|
Re: Statistical Considerations
|
1
|
Resverlogix Corp.
|
Mar 07, 2018 12:55PM
|
|
Re: off topic
|
1
|
Resverlogix Corp.
|
Oct 25, 2016 10:18AM
|
|
Re: So many questions...
|
1
|
Resverlogix Corp.
|
Dec 07, 2019 07:12AM
|
|
Re: EDITRe: i would love to hear,..
|
1
|
Resverlogix Corp.
|
Dec 07, 2019 07:19AM
|
|
Resverlogix poster from AHA 2016
|
1
|
Resverlogix Corp.
|
Nov 18, 2016 02:27PM
|
|
Re: Resverlogix tweeted a poster....
|
1
|
Resverlogix Corp.
|
Nov 20, 2016 01:09PM
|
|
Re: Cayman Chemical 1180 East Ellsworth Road Ann Arbor, Michigan 48108 USA
|
1
|
Resverlogix Corp.
|
Jan 16, 2017 06:16PM
|
|
Please add US BIOAF listing to the Stock Quote Sidebar
|
1
|
BIOASIS TECHNOLOGIES INC
|
May 20, 2016 11:18AM
|
|
Re: So many questions...
|
1
|
Resverlogix Corp.
|
Dec 07, 2019 07:20AM
|
|
Re: Delivery peptide conjugates of Trastuzumab
|
1
|
BIOASIS TECHNOLOGIES INC
|
Mar 20, 2018 11:33PM
|
|
Re: Bear Dsmc
|
1
|
Resverlogix Corp.
|
May 03, 2017 12:10PM
|
|
Re: Long awaited announcement just in…
|
1
|
BIOASIS TECHNOLOGIES INC
|
Jun 08, 2021 10:17AM
|
|
Merck lands positive PhIII for its CETP drug anacetrapib
|
1
|
Resverlogix Corp.
|
Jun 27, 2017 08:42AM
|
|
Re: Please add US BIOAF listing to the Stock Quote Sidebar
|
1
|
BIOASIS TECHNOLOGIES INC
|
May 20, 2016 11:28AM
|
|
Re: Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets
|
2
|
BIOASIS TECHNOLOGIES INC
|
Jun 21, 2022 08:08AM
|
|
Re: Resverlogix to press on with trial of cardiovascular drug after safety review
|
2
|
Resverlogix Corp.
|
Aug 15, 2016 12:13PM
|
|
biOasis Provides Further Details Regarding its Agreement with Rising Tide Equity
|
2
|
BIOASIS TECHNOLOGIES INC
|
Oct 25, 2016 10:29PM
|
|
Bioasis Announces Sale of Royalty Interest in LSD Enzymes Being Developed Under the Chiesi Group–Bioasis Strategic Alliance to XOMA Corporation
|
2
|
BIOASIS TECHNOLOGIES INC
|
Nov 04, 2020 05:32PM
|
|
Re: webcast
|
2
|
Resverlogix Corp.
|
Feb 26, 2016 06:13PM
|
|
Re: I'm glad the SSRA issue has finally been put to bed....
|
2
|
Resverlogix Corp.
|
Sep 18, 2018 09:48PM
|
